Literature DB >> 5082597

Isophosphamide as a new acrolein-producing antineoplastic isomer of cyclophosphamide.

R A Alarcon, J Meienhofer, E Atherton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5082597

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  7 in total

1.  In vitro binding of 3H-acrolein to regeneration rat liver DNA polymerase.

Authors:  N Munsch; A M de Recondo; C Frayssinet
Journal:  Experientia       Date:  1974-11-15

2.  Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics.

Authors:  Fei Li; Andrew D Patterson; Constance C Höfer; Kristopher W Krausz; Frank J Gonzalez; Jeffrey R Idle
Journal:  Biochem Pharmacol       Date:  2010-06-10       Impact factor: 5.858

3.  Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism.

Authors:  L D Lewis; D L Fitzgerald; P G Harper; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

Review 4.  The glycine deportation system and its pharmacological consequences.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  Pharmacol Ther       Date:  2012-05-11       Impact factor: 12.310

5.  Cigarette side-stream smoke lung and bladder carcinogenesis: inducing mutagenic acrolein-DNA adducts, inhibiting DNA repair and enhancing anchorage-independent-growth cell transformation.

Authors:  Hyun-Wook Lee; Hsiang-Tsui Wang; Mao-wen Weng; Chiu Chin; William Huang; Herbert Lepor; Xue-Ru Wu; William N Rom; Lung-Chi Chen; Moon-shong Tang
Journal:  Oncotarget       Date:  2015-10-20

6.  Metabolism of ifosfamide during a 3 day infusion.

Authors:  J M Hartley; L Hansen; S J Harland; P W Nicholson; F Pasini; R L Souhami
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

7.  Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide.

Authors:  R F Struck; D J Dykes; T H Corbett; W J Suling; M W Trader
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.